'2 d1' presentation slideshows

????????? ????

????????? ????. ????? ??????????????????????????? ( ALL ) ???????????? ( ANLL ) ?????? 3-4/10 ??????? 1/10 ??????? MICM ????????????????????????????????????????? 98% ? ALL ????? CR, 75% ?? 5 ???????? ANLL ?????????. ALL ??????. ???????? ????????????????????????????

1.15k views • 90 slides

Management of Locally Advanced NSCLC

Management of Locally Advanced NSCLC. Shilpen Patel MD FACRO Department of Radiation Oncology, University of Washington, Seattle, WA. Roadmap. Background Evolution of therapy Radiation alone Sequential chemotherapy and radiation Concurrent chemotherapy and radiation

828 views • 66 slides

Management of Locally Advanced NSCLC

Management of Locally Advanced NSCLC. Shilpen Patel MD FACRO Department of Radiation Oncology, University of Washington, Seattle, WA. Roadmap. Background Evolution of therapy Radiation alone Sequential chemotherapy and radiation Concurrent chemotherapy and radiation

802 views • 66 slides

Management of Locally Advanced NSCLC

Management of Locally Advanced NSCLC. Shilpen Patel MD FACRO Department of Radiation Oncology, University of Washington, Seattle, WA. Roadmap. Background Evolution of therapy Radiation alone Sequential chemotherapy and radiation Concurrent chemotherapy and radiation

994 views • 66 slides

Follicular Lymphoma Transformed Lymphoma Diffuse Large B-Cell Lymphoma

Follicular Lymphoma Transformed Lymphoma Diffuse Large B-Cell Lymphoma. John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine, Weill Cornell Medical College Associate Director, Weill Cornell Cancer Center.

829 views • 30 slides

Modern Information Retrieval Chapter 1: Introduction

Modern Information Retrieval Chapter 1: Introduction. Ricardo Baeza-Yates Berthier Ribeiro-Neto. Motivation. Example of the user information need Topic: NCAA college tennis team

1.52k views • 28 slides

Modern Information Retrieval Chapter 1: Introduction

Modern Information Retrieval Chapter 1: Introduction. Ricardo Baeza-Yates Berthier Ribeiro-Neto. Motivation. Example of the user information need Topic: NCAA college tennis team

347 views • 28 slides

Conventional Text-Retrieval Systems

Conventional Text-Retrieval Systems. Automatic Text Processing by G. Salton, Addison-Wesley, 1989. (Chapter 9). Database Management. A specified set of attributes is used to characterize each record. EMPLOYEE(NAME, SSN, BDATE, ADDR, SEX, SALARY, DNO)

413 views • 25 slides

Modern Information Retrieval Chapter 1: Introduction

Modern Information Retrieval Chapter 1: Introduction. Ricardo Baeza-Yates Berthier Ribeiro-Neto. Motivation. Example of the user information need Topic: NCAA college tennis team

371 views • 25 slides

Conventional Text-Retrieval Systems

Conventional Text-Retrieval Systems. Automatic Text Processing by G. Salton, Addison-Wesley, 1989. (Chapter 9). Database Management. A specified set of attributes is used to characterize each record. EMPLOYEE(NAME, SSN, BDATE, ADDR, SEX, SALARY, DNO)

263 views • 25 slides

Professor Jim Cassidy Cancer Research UK Department of Oncology University of Glasgow Glasgow, UK

440 views • 24 slides

What is the Optimal A pproach to CLL, BR vs. FCR/FR?

What is the Optimal A pproach to CLL, BR vs. FCR/FR?. Michael J. Keating MD Anderson Cancer Center Presented by: Richard R. Furman Weill Cornell Medical College. Bendamustine Bifunctional Antineoplastic Agent. CH 3. N. ClH 2 C. N. N. CO 2 H. Purine-like Benzimidazole Ring. ClH 2 C.

448 views • 23 slides

??????

??????. Date: Sep. 11, 2006. 1. ????????,?????????(????),???????? ??????( combined chemotherapy), ????,??,??,???. cyclophosphamide ( 750 mg/m 2 )+ cisplatin( 75 mg/m 2 ) (or carboplatin) q3w x 6 courses

373 views • 22 slides

??????

??????. Date: Sep. 11, 2006. 1. ????????,?????????(????),???????? ??????( combined chemotherapy), ????,??,??,???. cyclophosphamide ( 750 mg/m 2 )+ cisplatin( 75 mg/m 2 ) (or carboplatin) q3w x 6 courses

222 views • 22 slides

Induction chemotherapy TPF 3 Cycles Docetaxel 75mg/m 2 d1 Cisplatin 100mg/m 2 d1

Laryngoprotect-Study R. Knecht et al. Induction chemotherapy TPF 3 Cycles Docetaxel 75mg/m 2 d1 Cisplatin 100mg/m 2 d1 5-FU 1000mg/m 2 d1-4. Radiochemotherapy 70 Gy + Cisplatin 100 mg /m 2 d1, 22, 43. Regions and stages in %. 55%. T/N. N 0. N 2. N 3. N 1. ?.

363 views • 16 slides

Reviewer: Dr. Randeep Sangha Date posted: June 21, 2007

Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023 Authors: Hanna et al. Abstract # 7512.

164 views • 8 slides

Addressing LB 101 action items 81, 82, and 21

Addressing LB 101 action items 81, 82, and 21. Authors:. Date: 2008-03-17. Abstract. The document addresses LB 101 action items 81, 82, and 21. Action Items 81 & 82 (CIDs 960 & 879).

131 views • 4 slides